International Symposium On Protein Phosphorylation In Neurodegenerative Diseases.

International Symposium on Protein Phosphorylation in Neurodegenerative Diseases. January 2010

General Information

Meeting venue
The International Symposium on Protein Phosphorylation in Neurodegenerative Diseases will be held in the Santiago Grisolía Auditorium in the Museo de las Ciencias Príncipe Felipe of Valencia (Spain). The museum, designed by Valencian architect Santiago Calatrava, and with an auditorium of 2.800 square metres, provides the perfect venue for this symposium.

These emblematic projects have turned Valencia, with its heritage of over two thousand years of history, into a most modern city. The city is easily accessible by road, rail, sea and air. Its culture, cuisine and academic tradition along with its location on the Mediterranean coast and its pleasant climate, make the city the ideal setting for this symposium.

Program

PRELIMINARY PROGRAM

Phosphorylation/deposphorylation pathways and Alzheimer’s disease

Jesús Ávila. Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM). Madrid, Spain.
Tau phosphorylation in Alzheimer disease

Fred Van Leuven. Department of Human Genetics, Faculty of Medicine, KULeuven. Leuven, Belgium.
Amyloid activates GSK3 phosphorylates tau and kills neurons - as simple as that?

Angus Nairn. Department of Psychiatry, Yale University School of Medicine. New Haven, CT, USA.
Role of synaptic signaling in early stages of neurodegenerative diseases

Ottavio Arancio. Department of Pathology and Taub Institute, Columbia University. New York, USA.
Alzheimer’s disease: defeating it at the Synapse


Phosphorylation/deposphorylation pathways and Parkinson’s disease

Jie Shen. Brigham and Women’s Hospital, Harvard University Medical School. Boston, USA.
Synaptic dysfunction and neurodegeneration

Simone Engelender. Department of Pharmacology, Technion-Israel Institute of Technology. Haifa, Israel.
Regulation of the ubiquitylation of PD-related proteins by phosphorylation

Sabine Hilfiker. Institute of Parasitology and Biomedicine "López-Neyra", CSIC. Granada, Spain.
Compound parkin phosphorylation and aggregation

Edward A. Fon. Centre for Neuronal Survival and Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University. Montreal, Canada.
Parkin at the intersection of ubiquitin and kinase signaling

Ted M. Dawson. Institute for Cell Engineering, Johns Hopkins University School of Medicine. Baltimore, USA.
Kinases in Parkinson's disease: unexpected therapeutic opportunities

Mark R. Cookson. Laboratory of Neurogenetics, NIH. Bethesda, USA.
LRRK2 kinase activity and toxic effects in neurons

Kirsten Harvey. School of Pharmacy, University of London. London, UK.
Characterization of potential interactors of the multidomain kinase LRRK2


Phosphorylation/deposphorylation pathways and Huntington’s disease

Frédéric Saudou. Institut Curie. Orsay, France.
Huntington’s disease: from phosphorylation to function

Howard Schulman. Vice President, PPD Biomarker Discovery Sciences, Menlo Park. California, USA.
Proteomic-based discovery of the ubiquitin proteasome system in neurodegeneration


Phosphatases and neurodegeneration: old players revived

Estelle Sontag. Faculty of Health School, University of Newcastle. Callaghan NSW, Australia.
Role of PP2A methylation in neurodegeneration

Gilberto Fisone. Department of Neuroscience, Karolinska Institute. Stockholm, Sweden.
Exploring protein phosphorylation in Parkinson's disease with BAC transgenic mice

Jean-Antoine Girault. Institut du Fer à Moulin, INSERM and Pierre & Marie Curie University. Paris, France.
Regulation of genetic and epigenetic responses by kinases and phosphatases in striatal neurons